<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT138901183655N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2010-06-22</date_registration>
      <primary_sponsor>Research Vice- Chancellor of Nutrition and Health Faculty in Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Selenplus on Rheumatoid Arthritis</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Combined Antioxidant Supplementation on Blood Antioxidants indices, Lipid Peroxidation, Lipid Profile and Clinical Outcomes in Female Patients with Rheumatoid Arthritis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2010-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/3734</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment, Other design features: In the design of this study, confounding factors such as: dietary intake of foods and nutrients, body mass index and emotional stress level will be measured before and after the antioxidant intervention for adjusting the relationship of these variables with study outcomes.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Rheumatoid Arthritis.</hc_freetext>
      <i_freetext>Selenplus capsule(Eurovital company of Germany): Selenium 50mcg, Zinc 8mg, Vitamin A 400mcg, Vitamin C125mg, Vitamin E 40mg daily for 3 month duration.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Seyed Rafi Arefhosseini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nutrition and Health Faculty- Attar-e- Neishabori avenue- Golgasht avenue- Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 41 1335 7580</telephone>
        <email>arefhosseinir@tbzmed.ac.ir</email>
        <affiliation>Nutrition and Health Faculty in Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Seyed Rafi Arefhosseini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nutrition and Health Faculty- Attar-e- Neishabori avenue- Golgasht avenue- Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 41 1335 7580</telephone>
        <email>arefhosseinir@tbzmed.ac.ir</email>
        <affiliation>Health and Nutrition Faculty in Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: female rheumatoid arthritis patients who have ACR criteria 1987 for RA, age 40-60 yrs old, not changing the treatment protocol since 2 months prior to the study, mild to moderate disease severity, &#13;
Exclusion criteria: Presence of diabetes mellitus, hypertension, thyroid dysfunction, renal diseases, hepatic disorders, or Cushing’s syndrome, smoking or exposure to passive smoking, changing treatment and drugs, receiving antioxidant supplements</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>60 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M06.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Rheumatoid arthritis, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Selenplus capsule(Eurovital company of Germany): Selenium 50mcg, Zinc 8mg, Vitamin A 400mcg, Vitamin C125mg, Vitamin E 40mg daily for 3 month duration</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Blood Antioxidant Indices. Timepoint: twice: before and after 3 months. Method of measurement: all of parameters(superoxide dismutase, glutathione peroxidase, catalase, Total antioxidant capacity) by means of enzymatic kits except for catalase(with chemical substances) in Tabriz Pharmaceutical Research Center.</prim_outcome>
      <prim_outcome>Clinical Outcomes. Timepoint: twice: before and after 3 months. Method of measurement: by means of DAS-28 validated questionnaire.</prim_outcome>
      <prim_outcome>Lipid Profile. Timepoint: twice: before and after 3 months. Method of measurement: all parameters as HDL-C- Total cholesterol- triglyceride with enzymatic kits except LDL-c ( by means of Friedwald formula).</prim_outcome>
      <prim_outcome>Lipid Peroxidation. Timepoint: twice: before and after 3 months. Method of measurement: by chemical substances in Tabriz Pharmaceutical Research Center.</prim_outcome>
      <prim_outcome>Serum Arylesterase Enzyme. Timepoint: twice: before and after 3 months. Method of measurement: by chemical substances in Tabriz Pharmaceutical Research Center.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Emotional Stress Level. Timepoint: twice: before and after 3 months. Method of measurement: by validated emotional stress questionnaire- assissted by MSc psychology practioner.</sec_outcome>
      <sec_outcome>Dietary Intake of Energy, Nutrients and Comparison with RDA. Timepoint: twice: before and after 3 months. Method of measurement: by validated  dietary questionnaires: FFQ and 24- hr recall questionnaire for 3 days- calculated by Nutritionist 3 software.</sec_outcome>
      <sec_outcome>Weight. Timepoint: twice: before and after 3 months. Method of measurement: weighed by digital scales with 0.1 kg sensitivity.</sec_outcome>
      <sec_outcome>Body Mass Index (BMI). Timepoint: twice: before and after 3 months. Method of measurement: calculated with Quetlet's formula(weight(kg)/(height*height(m))).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Rheumatology Research, Faculty of Medicine, Tabriz University of Medical Sciences</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Research Vice- Chancellor of Nutrition and Health Faculty in Tabriz University of Medical Sciences</source_name>
      <source_name>Rheumatology Research, Faculty of Medicine, Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2010-07-06</approval_date>
        <contact_name>Research Vice- Chancellor of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Research Vice- Chancellor of Tabriz University of Medical sciences, Attar-e-Neishabori avenue, Golgasht avenue, Tabriz Tabriz  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
